ARTICLE | Company News
Crucell, University Medical Center Utrecht deal
May 21, 2001 7:00 AM UTC
CRXL will use its MAbstract phage display technology to identify targets and develop antibodies, and its PER.C6 cell line expression platform to develop vaccines for Type II diabetes. Resulting compou...